Egypt Addiction Therapeutics Market Analysis

Egypt Addiction Therapeutics Market Executive Summary

Egypt addiction therapeutics market was valued at $28 Mn in 2022 and is estimated to reach $54 Mn in 2030, exhibiting a CAGR of 8.4% during the forecast period.

Addiction is a medical condition that includes obsessive drug seeking and consumption behaviour despite its negative effects. Addiction therapeutics utilizes medications and psychological interventions that have been scientifically proven to help people stop using drugs and alcohol while also treating the underlying causes of their addiction. Personalized care in addiction treatment considers a range of variables, including the kind of addiction, the intensity of the drug use disorder, co-occurring mental health disorders, social support networks, personal preferences, and any underlying medical conditions. In order to assist long-term recovery, addiction therapies collaborate to develop a complete treatment plan that may incorporate behavioural therapy, medication, counselling, support groups, and other research-proven techniques.

Addiction is a major health concern in Egypt, affecting people of all ages and socioeconomic backgrounds. Addiction to nicotine, primarily from smoking, is still common in both adults and adolescents, with 90% of teenagers familiar with tobacco. The most popular illicit substance, hashish, has a varying prevalence of use. In 2022, 5.3% of secondary school students and 3.6% of university students were consuming illicit substances. Concerns are also raised by the growing abuse of opioids like tramadol and tranquilizers, which are abused by 4% of college students. When it comes to substance addiction, men typically show higher rates than women. Teenagers and young adults are more likely to abuse drugs, which is probably due to things like peer pressure, trying new things, and having fewer opportunities. Addiction impact varies geographically; it may be higher in urban locations like Cairo than in rural areas.

The market for addiction treatments has seen significant growth, led by Egyptian Pharma Holding Company (EPHC), which is developing local production of essential medications for addiction therapy such as buprenorphine and naltrexone in collaboration with foreign partners. This calculated action attempts to improve the price of these drugs and their accessibility for addicting patients. Furthermore, Pharco Pharmaceutical Industries has made noteworthy progress by opening a specialized facility dedicated to producing drugs for the treatment of addiction and chronic pain, strengthening Egypt's domestic supply chain for these vital therapeutics.

Market Dynamics

Market Growth Drivers

Changing Societal Attitudes and Reduced Stigma: As a result of a gradual shift in society's perceptions of addiction as a medical condition rather than a moral failing, stigma has diminished. This change makes people more likely to seek treatment, which raises the demand for comprehensive, easily available addiction therapy and fuels the market's growth.

High Burden of Addiction: There is a significant demand for effective and accessible treatment options due to the large number of people who suffer from addiction. Addiction treatment services see a corresponding boom in growth and expansion at the same time that addiction rates continue to rise sharply. More inventive, comprehensive, and easily available therapeutic solutions are required as a result of the growing market need for efficient therapies that address the wide variety of chemicals that cause addiction. Due to the urgent need to address the rising prevalence of addiction, interventions, drugs, and holistic approaches are being developed and made available, which is propelling the expansion of the addiction treatment market in Egypt.

Increasing Awareness and Recognition: Due to rising attempts to address addiction and growing awareness of substance abuse as a severe public health concern, there is a growing need for new addiction therapy medications and therapies. The growing awareness of addiction as a significant public health concern will lead to an expansion in the market for addiction therapy.

Market Restraints

Regulatory Challenges: The Egyptian Drug Authority (EDA) and other regulatory agencies have strict compliance standards and regulatory processes that could make it difficult to introduce novel drugs for addiction treatment onto the market. Complicated registration processes, strict quality standards, and lengthy approval processes could make it more difficult for new drugs to reach the market on time.

Stigma and Perception: The social stigma associated with addiction may prevent some people from getting the help they need. Addicts may be hindered from seeking treatment by societal attitudes and false beliefs that view addiction as a moral failing rather than a medical illness, which could impact the market for medications used in addiction therapy.

Limited Public Awareness: The public may still be unaware of all the options for treatment, even in spite of government initiatives to increase public knowledge of addiction and available options. The demand for medications and other services for the treatment of addiction may be impacted by this ignorance, preventing the market's expansion.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Population (MoHP) in Egypt is an important entity in establishing healthcare policies and managing the regulatory environment for drugs utilized as addiction therapeutics. The MoHP works alongside organizations such as the Egyptian Drug Authority (EDA) to guarantee that these drugs meet strict safety, effectiveness, and labelling requirements prior to being put on the market. The Egypt Drug Authority (EDA) regulates import, distribution, and licensing requirements for medicines. Guidelines for treatment protocols are developed, with an emphasis on a multifaceted strategy that includes behavioural therapies, pharmaceuticals, and support services. The focus may be on increasing the availability and affordability of medications used in addiction treatment, and pharmacovigilance and quality control procedures guarantee continuous monitoring of the safety and effectiveness of drugs.

Competitive Landscape

Key Players

• Indivior
• Alkermes
• Reckitt Benckiser
• Otsuka Pharmaceutical Co.
• Pfizer
• Mallinckrodt
• Purdue Pharma L.P.
• GlaxoSmithKline
• Teva Pharmaceutical
• Novartis.